ALC-0159

ALC-0159 is primarily used as a PEG-lipid component in mRNA-LNP formulations (e.g., Pfizer-BioNTech COVID-19 vaccine) to enhance nanoparticle stability, reduce immunogenicity, and prolong circulation time by steric stabilization. While critical for vaccine efficacy and shelf-life extension, its potential association with rare allergic reactions and prolonged elimination half-life requires careful safety evaluation.